YMC to acquire pharmaceutical systems’ business

YMC Co., Ltd., a sup­pli­er of sep­a­ra­tions resins, ser­vices and sys­tems for the phar­ma­ceu­ti­cal mar­ket, announced that they entered a for­mal agree­ment to acquire the phar­ma­ceu­ti­cal sys­tems busi­ness of Lewa-Nikkiso Amer­i­ca Inc. Based in Devens, MA, USA this group with­in the Lewa divi­sion of Nikkiso Cor­po­ra­tion is a suc­cess­ful provider of advanced pro­duc­tion scale chro­matog­ra­phy sys­tems for the bio­pro­cess­ing and the phar­ma­ceu­ti­cal industry.
The acqui­si­tion com­ple­ments YMC’s exist­ing offer­ing of chro­matog­ra­phy columns, sys­tems, ser­vices and con­sum­ables and allows YMC to strength­en its reach in North Amer­i­ca and expand its glob­al sys­tems’ busi­ness. The trans­ac­tion includes staff and assets ded­i­cat­ed to the devel­op­ment, man­u­fac­ture and sales of batch and con­tin­u­ous HPLC, LPLC, SMB and buffer / caus­tic dilu­tion sys­tems for the bio/pharmaceutical mar­ket. This includes the man­u­fac­tur­ing site locat­ed in Devens, MA, USA. Terms of the agree­ment were not made public.

Better position to capture global growth trends

Togeth­er with this group, YMC expects to offer its glob­al cus­tomers an even more com­pre­hen­sive port­fo­lio of purifi­ca­tion-enabling prod­ucts. YMC’s glob­al sales reach is expect­ed to accel­er­ate the for­mer Lewa bio/pharmaceutical group’s busi­ness. The com­bined oper­a­tions will be well posi­tioned to cap­ture glob­al growth trends, such as grow­ing demand for con­tin­u­ous processing.
Lewa remains a key ele­ment of the busi­ness through a long term pump sup­ply arrange­ment. The Lewa pumps are a basis for the Eco­Prime LPLC, HPLC, SMB, Con­tin­u­ous Chro­matog­ra­phy and BID sys­tems. The deal includes the trans­fer of licens­es with Chro­ma­Con AG and Bay­er AG that sup­port the bio/pharmaceutical sys­tems busi­ness and cer­tain non-com­pete clauses.